These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 12064467)

  • 1. Have p53 gene mutations and protein expression a different biological significance in colorectal cancer?
    Bazan V; Migliavacca M; Tubiolo C; Macaluso M; Zanna I; Corsale S; Amato A; Calò V; Dardanoni G; Morello V; La Farina M; Albanese I; Tomasino RM; Gebbia N; Russo A
    J Cell Physiol; 2002 May; 191(2):237-46. PubMed ID: 12064467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 mutations in L3-loop zinc-binding domain, DNA-ploidy, and S phase fraction are independent prognostic indicators in colorectal cancer: a prospective study with a five-year follow-up.
    Russo A; Migliavacca M; Zanna I; Valerio MR; Latteri MA; Grassi N; Pantuso G; Salerno S; Dardanoni G; Albanese I; La Farina M; Tomasino RM; Gebbia N; Bazan V
    Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1322-31. PubMed ID: 12433709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoreactivity evaluation of mutant p53 gene product with DNA ploidy pattern in colorectal carcinoma.
    Nasif WA; El-Emshaty HM; Tabll A; Elmasry SA; Attallah AM; Gad Elhak NA
    Hepatogastroenterology; 2004; 51(58):1001-6. PubMed ID: 15239234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers.
    Akkiprik M; Ataizi-Celikel C; Düşünceli F; Sönmez O; Gulluoglu BM; Sav A; Ozer A
    J Gastrointestin Liver Dis; 2007 Mar; 16(1):11-7. PubMed ID: 17410283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Staining patterns of p53 immunohistochemistry and their biological significance in colorectal cancer.
    Kaserer K; Schmaus J; Bethge U; Migschitz B; Fasching S; Walch A; Herbst F; Teleky B; Wrba F
    J Pathol; 2000 Mar; 190(4):450-6. PubMed ID: 10699994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
    Chang SC; Lin JK; Lin TC; Liang WY
    Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P53 mutations in colorectal cancer from northern Iran: Relationships with site of tumor origin, microsatellite instability and K-ras mutations.
    Mahdavinia M; Bishehsari F; Verginelli F; Cumashi A; Lattanzio R; Sotoudeh M; Ansari R; Semeraro D; Hormazdi M; Fakheri H; Rakhshani N; De Lellis L; Curia MC; Cama A; Piantelli M; Malekzadeh R; Iacobelli S; Mariani-Costantini R
    J Cell Physiol; 2008 Aug; 216(2):543-50. PubMed ID: 18330889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral response to p53 is associated with conserved domains II and IV mutations in human colorectal cancer: a case-control study in Taiwan.
    Wu CM; Tang R; Chen JR; Wu MC; Chien HT; Changchien CR; Hsieh LL
    Oncol Rep; 2004 Nov; 12(5):1045-51. PubMed ID: 15492791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
    de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
    Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial and nutritional risk factors for p53 overexpression in colorectal cancer.
    Freedman AN; Michalek AM; Marshall JR; Mettlin CJ; Petrelli NJ; Black JD; Zhang ZF; Satchidanand S; Asirwatham JE
    Cancer Epidemiol Biomarkers Prev; 1996 Apr; 5(4):285-91. PubMed ID: 8722220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational spectra of p53 in geographically localized esophageal squamous cell carcinoma groups in China.
    Cao W; Chen X; Dai H; Wang H; Shen B; Chu D; McAfee T; Zhang ZF
    Cancer; 2004 Aug; 101(4):834-44. PubMed ID: 15305417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum anti-p53 in relation to mutations across the entire translated p53 gene in colorectal carcinomas.
    Forslund A; Kressner U; Lindmark G; Inganäs M; Lundholm K
    Int J Oncol; 2001 Sep; 19(3):501-6. PubMed ID: 11494027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of analysis of p53 alteration and observation of surface microstructure for diagnosis of ulcerative colitis-associated colorectal neoplasia.
    Fujii S; Fujimori T; Chiba T
    J Exp Clin Cancer Res; 2003 Mar; 22(1):107-15. PubMed ID: 12725330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas.
    Bernardini S; Adessi GL; Billerey C; Chezy E; Carbillet JP; Bittard H
    J Urol; 1999 Oct; 162(4):1496-501. PubMed ID: 10492244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study.
    Bazan V; Migliavacca M; Zanna I; Tubiolo C; Corsale S; Calò V; Amato A; Cammareri P; Latteri F; Grassi N; Fulfaro F; Porcasi R; Morello V; Nuara RB; Dardanoni G; Salerno S; Valerio MR; Dusonchet L; Gerbino A; Gebbia N; Tomasino RM; Russo A
    J Cancer Res Clin Oncol; 2002 Dec; 128(12):650-8. PubMed ID: 12474051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TP53 in gastric cancer: mutations in the l3 loop and LSH motif DNA-binding domains of TP53 predict poor outcome.
    Migliavacca M; Ottini L; Bazan V; Agnese V; Corsale S; Macaluso M; Lupi R; Dardanoni G; Valerio MR; Pantuso G; Di Fede G; Tomasino RM; Gebbia N; Mariani-Costantini R; Russo A
    J Cell Physiol; 2004 Sep; 200(3):476-85. PubMed ID: 15254976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of AIB1 overexpression with advanced clinical stage of human colorectal carcinoma.
    Xie D; Sham JS; Zeng WF; Lin HL; Bi J; Che LH; Hu L; Zeng YX; Guan XY
    Hum Pathol; 2005 Jul; 36(7):777-83. PubMed ID: 16084947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
    Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
    Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers.
    Kropveld A; Rozemuller EH; Leppers FG; Scheidel KC; de Weger RA; Koole R; Hordijk GJ; Slootweg PJ; Tilanus MG
    Lab Invest; 1999 Mar; 79(3):347-53. PubMed ID: 10092071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.